On May 5th, we hosted a Global Communication in Life Sciences Take 30 session to discuss the pitfalls and strategies surrounding Codes of Conduct. Our panelist was accomplished attorney and ethics specialist, Anne Norris, Principal of Optimum Integrity, LLC.
While our conversation was wide-ranging, below are some of the key takeaways:
1 – A company’s Code of Conduct is the foundational building block of an ethics and compliance program. It is the vehicle through which the organization communicates its core values and high level expectations for all of its employees.
2 – If you’re taking your Code global or international, be sure to work with an experienced Language Service Provider (LSP). Your LSP will assign linguists with the appropriate background, possessing expertise in helping to manage the in-country review process. The linguists will also be able to offer superior project management to accommodate changes along the way. Be sure to keep the Code simple and visually appealing for all readers. And remember, the consequences of not having a translated Code of Conduct can be quite severe! Contact me to hear more on this.
3 – While the Code itself is the building block, companies need to identify ways to further engage their employees and promote ethical behavior. Efforts for consideration include:
Codes of Conduct are truly more than words on paper. In my opinion, they represent an organization’s ethics DNA. I was happy to be a part in this valuable Take 30. If you’re interested, read more on this topic in my Q&A post with Anne Norris here.
I look forward to your participation in our Take 30 calls in the future. Please take a moment to request membership in the LinkedIn Group today!
Regional Sales Director
Lionbridge Life Sciences
by Kelvin Chan, Head of Sales, South Asia at Lionbridge
As one of the largest annual biopharmaceutical conventions in Asia, the Biopharma Asia Meeting recently concluded its 8th program in sunny Singapore. Lionbridge was the sponsor of the opening cocktail reception, our first official participation at this high-profile convention.
Against the stoic backdrop of the nation-state mourning the recent passing of the founder of modern Singapore, Mr. Lee Kuan Yew, the event’s success was a strong endorsement of the former Prime Minister’s contributions to the transformation of Singapore’s economy. The Life Sciences sector has been earmarked one of the 4 pillars of the high-growth Singapore economy by its government for more than a decade.
The level of investment in the Life Sciences industry, and more importantly, the value that the industry brings to the human population, is second to none. Pharmaceuticals and biotechs are under enormous pressure— and deservingly incentivized— to bring safe and effective drugs, medicines and vaccines to the market as quickly as possible. It is not surprising, then, that the clinical trial space and innovations within this space that drive market acceleration, patient safety and financial efficiencies have remained hot topics at the convention over the years.
I had the opportunity to attend one of the biggest roundtables at the event: The Pan-Asian Clinical Trials Coordination, hosted by Dr. Karen Wai, Quintiles. Here are 3 takeaways from the roundtable— and the convention as a whole— on how to boost your Life Sciences business in Asia as if it were “on drugs” as they say!
1) Rely on trusted and experienced partners
2) Prioritize process consistency
3) Build a great internal corporate culture
There are no magic pills in successfully growing a regional or international business, but I hope that these 3 observations will be useful to you as you consider all your growth strategies for your business in Asia.
Last, I would like to share with you a picture of the Lionbridge team at the opening cocktail reception that we sponsored. If you couldn’t make it this year, you did miss out a great opportunity. But not to worry— we do hope to see you at the next round come 2016!
Analysts are in agreement that, while the 2014 global medical device market was a challenging year, it wasn’t a slow year. As reported in MDDOnline, Kalorama Research pegged the global market for medical devices at $361 billion in 2014, up from $330 billion in 2013.
What were some of the notable industry drivers?
Big Data is moving from back room to center stage.
Medical devices are generating more and more data, and even with regulatory and liability concerns, companies are seeking ways to utilize this valuable asset. A big contributor? Wearable technologies with $5.2 billion in global sales in 2014.
Despite the challenges surrounding increased regulations and evolving clinical standards, conducting clinical trials globally is an attractive option for life sciences organizations. But communication in clinical trials must evolve to meet the demands of the changing clinical landscape, with patient recruitment and retention communications at the forefront.
Here are 3 things to consider for improving your patient recruitment communications:
Continue reading »
We recently held our first Take 30 interactive discussion with members of our LinkedIn Group, Global Communication in Life Sciences. Our topic, “Don’t Go Global, Go Local,” sparked lively conversation among Group members. Here are some useful takeaways inspired by our discussion: Continue reading »
Developing content and controlling revisions is a particularly critical process in the highly regulated Life Sciences industry. The slightest mistakes can rapidly find their way through a connected chain of internal and market-facing documentation, leaving those responsible with the painful and problematic dilemma of catching all of the errors throughout the documents and online sites all over the world. The problem grows exponentially when this documentation is localized. Revisions to translated content increase time to market and of course the costs. Continue reading »
In many global life sciences organizations, individual markets manage their own translation, either through working from content developed by the corporate office or creating their own. This model supports the local interest; however, as the volume of content and the number of languages grow due to regional expansion, and as cross-discipline life science content integration becomes important, the inefficiencies of decentralization become more obvious.
As we approach a New Year, now may be a good time to consider centralizing your translation efforts. Here are some considerations as you evaluate this model:
Optimized Technologies are Proven and Readily Deployable: In the past, the resources necessary for seamless centralization were not readily available. However, today, the systems needed to facilitate multilingual content development with local input and validations are being successfully deployed by life sciences organizations worldwide. The deployment model involves central control of the process, in tandem with a globally capable language service provider that can seamlessly support an organization’s local operations and protocols, like Lionbridge Life Sciences.
Your Total Translation Costs May be Actually Higher Than You Realize: Translation costs have a multitude of ways of presenting themselves—as pass-through costs from outside agencies at the project level, at the clinical level on research initiatives, and as costs subsumed in local budgets at the regional and branch levels. Adding these costs up could serve as the impetus to realizing there may be a better way.
Achieving Higher Levels of Quality and Efficiency May Be Gained Through Outside Expertise: In each country, standards and protocols vary tremendously, so there may be apprehension surrounding regulatory compliance. As we know, the only constant in today’s evolving global regulatory environment is that local health authorities expect on-time, quality submissions each and every time. Whether you are registering across all EU languages with the European Medicines Agency (EMA), or a select number of languages with local health authorities in China (SFDA), Japan (PMDA), and Korea (KFDA) among others, a broad range of multilingual regulatory submission needs from translation to desktop publishing to XML engineering and independent review are part and parcel to ongoing operations. An outside resource with a proven track record in successful global regulatory submissions may be a benefit to achieving greater efficiencies in the prevailing ‘do more with less’ life science environments, particularly in regulatory functions.
What might the benefits of a centralized model be?
More and more life sciences companies are considering a centralized translation strategy as they bring in a new content management system or an e-learning platform in order to fully transform their global communications model for the digital world.
Centralization makes everything transparent: costs, timelines and quality. Ultimately, though, centralization is not about getting something for less. The real value to life sciences organizations lies in the competitive advantages derived from improving quality, predictability, consistency, strategic use of resources, and the ability of the organization to quickly respond to emerging opportunities and obstacles.
As you plan to further optimize your resources in 2015, how can Lionbridge Life Sciences help you with a centralized translation model to ensure global consistency and local relevance across customers and markets?
Patient recruitment is mandatory for all phases of clinical trials, yet it’s often treated like a distant afterthought. Patient recruitment delays are the main reason why clinical trials fail to complete on time. CW Weekly cited results from research conducted by Cutting Edge Information that an estimated 80% of trials fail to meet enrollment timelines, with as many as 50% of research trial sites enrolling one or no patients. These factors can cause a trial sponsor to lose millions of dollars by having to extend study timelines—subsequently delaying the drug’s regulatory clearance and greatly impacting sales. Continue reading »
Today, the life sciences industry is a key contributor to Singapore’s growing economy: more than 30 of the world’s leading biomedical sciences companies (including GSK, Novartis and Takeda) consider Singapore an ideal location to fuel innovation. In fact, Singapore is on a fast track to becoming the Biopolis of Asia, a leading international biomedical sciences cluster, according to Singapore’s Economic Development Board.
Here are 3 things to know as you consider expanding your life sciences activities in Singapore:
1. Singapore provides a strong scientific foundation – offering seven research institutes and five research consortia spanning clinical sciences, genomics, bioengineering, molecular/cell biology, medical biology, bio-imaging and immunology. Many ongoing programs are underway to address a variety of pressing health-related issues, including:
2. Singapore sponsors several initiatives to attract premier clinician investigators to lead transformative clinical research. The STaR Investigator Award is one such initiative. The award includes a sizable 5-year research grant, an annual salary, and a one time start-up investment of up to $500,000. Investigators are required to commit to a full-time appointment, and the research must be conducted in Singapore.
3. Singapore is home to Lionbridge Life Sciences’ recently expanded Center of Excellence in Asia Pacific, exclusively dedicated to serving the needs of life sciences organizations large and small in this growing region. We support over 250 language combinations that include numerous Asian and Indic languages such as Bahasa Indonesian, Bahasa Malay, Cebuano, Simplifed Chinese, Traditional Chinese for Taiwan, Traditional Chinese for Hong Kong, Korean, Filipino, Hiligaynon, Japanese, the list goes on. Our highly skilled translators are in-country native speakers with life sciences backgrounds. We also have in-depth experience supporting regulatory document submissions to virtually all health authorities in Asia including CFDA, JFDA and MFDS.
If you’re thinking about expanding your life sciences activity in Singapore, and if you consider flawless, timely delivery of multilingual content mission-critical to global success, put our comprehensive life sciences experience to work for you. Read our Asia-Pacific solutions brief here.
In the world of localization, life sciences is different from any other industry because of the unique nature of its requirements. With regulations changing on a continual basis, a premium is placed on quality above all else.
The Life Sciences Business Roundtable offers the ideal forum for senior professionals in all verticals of the life sciences industry – localization included – to meet, share knowledge, discuss trends and impact associated with their line of the business. At the most recent Roundtable in Dublin last month, we presented an agenda of hot topics related to life sciences content and translation management systems, new e-labeling EU requirements, and digital marketing in life sciences. The program was topped by an interesting presentation on the medical technology sector in Ireland by Mr. Donal Balfe, Vice President of Global Manufacturing RMS for Covidien and vice-chairman of the Irish Medical Devices Association (IMDA). IMDA is an association of entrepreneurial sales, marketing and distribution organizations that bring innovative medical technologies to market, whose vision is that Ireland will be a global leader in patient-centric medical technologies. Continue reading »